Value of Exclusive Indication and Regulatory Approval

Bayer's Adempas (active ingredient: riociguat) received official approval on October 8, 2013, from the U.S. Food and Drug Administration (FDA) through the Priority Review pathway, designated as NDA 204819. This drug was developed as the first-in-class soluble Guanylate Cyclase stimulator (sGC stimulator), and it achieved a significant milestone by becoming the first approved treatment for patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) who are inoperable or have experienced recurrence after surgery. This swift approval by regulatory authorities simultaneously demonstrates Adempas's unique clinical value and strong market entry barrier in the rare pulmonary disease market, where adequate treatment options were previously lacking.

Blockbuster-Level Revenue Growth and Market Dominance

Since its market launch, Adempas has consistently expanded its prescription base, establishing itself as a core pharmaceutical asset for Bayer. In fact, Adempas's annual global revenue has shown steady growth, reaching 721 million euros in 2023 and 745 million euros (approximately 800 million USD) in 2024. The increase in prescriptions, particularly in the U.S. market, is driving overall performance, indicating high confidence in Adempas as a long-term treatment option for patients with Pulmonary Arterial Hypertension (PAH). This stable cash flow provides a solid financial foundation for the development of late-stage pipeline products.

Synergistic Strategic Partnerships with Global Big Pharma

In May 2014, Bayer formed a partnership with global pharmaceutical company Merck (MRK) (known as MSD outside of the U.S. and Canada) by entering into a joint development and commercialization agreement in the field of sGC modulators. In this deal, Merck paid Bayer a $1 billion USD upfront payment and agreed to pay up to $1.1 billion in milestone payments, completing a total $2.1 billion deal based on the achievement of commercial milestones. By sharing the development costs and global revenues of Adempas and Verquvo (active ingredient: vericiguat), a next-generation treatment for heart failure, the two companies have maximized marketing efficiency and rapidly expanded their global distribution network.

Intensifying Competitive Landscape and Future Market Outlook

The PAH market is currently valued at approximately $8.07 billion to $8.93 billion as of 2026 and is projected to expand to as much as $14.3 billion in the early 2030s. In line with market growth, competition is intensifying with existing market leaders such as Johnson & Johnson's Opsumit (active ingredient: macitentan) and Uptravi (active ingredient: selexipag). Furthermore, with Merck's approval of Winrevair (active ingredient: sotatercept), an innovative activin signaling inhibitor, in March 2024, the market landscape is changing, and Bayer needs to accelerate its sophisticated differentiation strategies and combination therapy clinical trials to maintain its existing exclusive position.